ArticleJournal of clinical hypertension (Greenwich, Conn.)2025
Photoplethysmography-Derived Arterial Stiffness Index Delivered Greater Cardiovascular Prevention Value to Non-Elderly: A Retrospective Cohort Study Based on UK Biobank.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Photoplethysmography-derived arterial stiffness index (ASI) has been proven to be associated with various cardiovascular diseases. The present study aims to determine whether the predictive value of ASI varies between elderly and non-elderly and whether ASI improves the discrimination and reclassification ability of the updated Systematic Coronary Risk Evaluation (SCORE2) in different age groups. This retrospective study included UK Biobank participants with ASI recordings. Multivariable Cox proportional hazard models were used to estimate the associations between ASI and major adverse cardiovascular events (MACE) in different age groups. The difference in C-statistic, integrated discrimination improvement (IDI), and continuous net reclassification improvement (NRI) were calculated to test the predictive performance of ASI beyond SCORE2 in the elderly and non-elderly. A total of 127 045 participants were included in the primary analysis. During a median of 11.7 years, 2606 (10.7%) and 4408 (4.3%) MACE were identified in the elderly and non-elderly, respectively. The non-elderly exhibited a greater extent of increased risk for MACE with higher ASI (HR, 1.314 [1.280-1.350] vs. HR, 1.066 [1.026-1.107]). Furthermore, the IDI and continuous NRI of ASI beyond SCORE2 for MACE were more than two times higher for non-elderly individuals than their elderly counterparts (IDI, 0.0481% [0.0182%-0.0953%] vs. IDI, 0.0010% [-0.0052% to 0.0295%]; NRI, 8.76% [6.83% to 10.60%] vs. NRI, 3.27% [-3.92% to 5.97%]). Our findings suggested that ASI should primarily be utilized for primary cardiovascular prevention in individuals below 65.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.